{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:10:50Z","timestamp":1777500650100,"version":"3.51.4"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Comput Sci"],"DOI":"10.1038\/s43588-020-00007-6","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T17:03:37Z","timestamp":1610643817000},"page":"33-41","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies"],"prefix":"10.1038","volume":"1","author":[{"given":"Gihanna","family":"Galindez","sequence":"first","affiliation":[]},{"given":"Julian","family":"Matschinske","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5491-7330","authenticated-orcid":false,"given":"Tim Daniel","family":"Rose","sequence":"additional","affiliation":[]},{"given":"Sepideh","family":"Sadegh","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7562-1018","authenticated-orcid":false,"given":"Marisol","family":"Salgado-Albarr\u00e1n","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4562-5816","authenticated-orcid":false,"given":"Julian","family":"Sp\u00e4th","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0282-0462","authenticated-orcid":false,"given":"Jan","family":"Baumbach","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9565-1903","authenticated-orcid":false,"given":"Josch Konstantin","family":"Pauling","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,1,14]]},"reference":[{"key":"7_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41\u201358 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"7_CR2","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.tips.2019.06.003","volume":"40","author":"MD Paranjpe","year":"2019","unstructured":"Paranjpe, M. D., Taubes, A. & Sirota, M. Insights into computational drug repurposing for neurodegenerative disease. Trends Pharmacol. Sci. 40, 565\u2013576 (2019).","journal-title":"Trends Pharmacol. Sci."},{"key":"7_CR3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/bib\/bbr047","volume":"12","author":"P Sanseau","year":"2011","unstructured":"Sanseau, P. & Koehler, J. Computational methods for drug repurposing. Brief. Bioinform. 12, 301\u2013302 (2011).","journal-title":"Brief. Bioinform."},{"key":"7_CR4","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.drudis.2020.04.005","volume":"25","author":"G Ciliberto","year":"2020","unstructured":"Ciliberto, G. & Cardone, L. Boosting the arsenal against COVID-19 through computational drug repurposing. Drug Discov. Today 25, 946\u2013948 (2020).","journal-title":"Drug Discov. Today"},{"key":"7_CR5","doi-asserted-by":"publisher","first-page":"D36","DOI":"10.1093\/nar\/gks1195","volume":"41","author":"DA Benson","year":"2013","unstructured":"Benson, D. A. et al. GenBank. Nucleic Acids Res. 41, D36\u2013D42 (2013).","journal-title":"Nucleic Acids Res."},{"key":"7_CR6","doi-asserted-by":"crossref","unstructured":"Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data \u2013 from vision to reality. Euro Surveill. 22, (2017).","DOI":"10.2807\/1560-7917.ES.2017.22.13.30494"},{"key":"7_CR7","doi-asserted-by":"publisher","first-page":"D193","DOI":"10.1093\/nar\/gkl929","volume":"35","author":"The UniProt Consortium.","year":"2007","unstructured":"The UniProt Consortium. The Universal Protein Resource (UniProt). Nucleic Acids Res. 35, D193\u2013D197 (2007).","journal-title":"Nucleic Acids Res."},{"key":"7_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman, H. M. The Protein Data Bank. Nucleic Acids Res. 28, 235\u2013242 (2000).","journal-title":"Nucleic Acids Res."},{"key":"7_CR9","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ng.2653","volume":"45","author":"GTEx Consortium.","year":"2013","unstructured":"GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45, 580\u2013585 (2013).","journal-title":"Nat. Genet."},{"key":"7_CR10","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gku476","volume":"42","author":"Q Duan","year":"2014","unstructured":"Duan, Q. et al. LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures. Nucleic Acids Res. 42, W449\u2013W460 (2014).","journal-title":"Nucleic Acids Res."},{"key":"7_CR11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","volume":"583","author":"DE Gordon","year":"2020","unstructured":"Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583, 459\u2013468 (2020).","journal-title":"Nature"},{"key":"7_CR12","doi-asserted-by":"publisher","first-page":"D661","DOI":"10.1093\/nar\/gkn794","volume":"37","author":"V Navratil","year":"2009","unstructured":"Navratil, V. et al. VirHostNet: a knowledge base for the management and the analysis of proteome-wide virus-host interaction networks. Nucleic Acids Res. 37, D661\u2013D668 (2009).","journal-title":"Nucleic Acids Res."},{"key":"7_CR13","doi-asserted-by":"publisher","first-page":"D583","DOI":"10.1093\/nar\/gku1121","volume":"43","author":"T Guirimand","year":"2015","unstructured":"Guirimand, T., Delmotte, S. & Navratil, V. VirHostNet 2.0: surfing on the web of virus\/host molecular interactions data. Nucleic Acids Res. 43, D583\u2013D587 (2015).","journal-title":"Nucleic Acids Res."},{"key":"7_CR14","doi-asserted-by":"publisher","first-page":"D536","DOI":"10.1093\/nar\/gkv1115","volume":"44","author":"M Kotlyar","year":"2016","unstructured":"Kotlyar, M., Pastrello, C., Sheahan, N. & Jurisica, I. Integrated interactions database: tissue-specific view of the human and model organism interactomes. Nucleic Acids Res. 44, D536\u2013D541 (2016).","journal-title":"Nucleic Acids Res."},{"key":"7_CR15","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk, D. et al. STRING v11: protein\u2013protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607\u2013D613 (2019).","journal-title":"Nucleic Acids Res."},{"key":"7_CR16","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1093\/bioinformatics\/bty114","volume":"34","author":"B Percha","year":"2018","unstructured":"Percha, B. & Altman, R. B. A global network of biomedical relationships derived from text. Bioinformatics 34, 2614\u20132624 (2018).","journal-title":"Bioinformatics"},{"key":"7_CR17","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.1021\/acs.jproteome.0c00316","volume":"19","author":"X Zeng","year":"2020","unstructured":"Zeng, X. et al. Repurpose open data to discover therapeutics for COVID-19 using deep learning. J. Proteome Res. 19, 4624\u20134636 (2020).","journal-title":"J. Proteome Res."},{"key":"7_CR18","doi-asserted-by":"publisher","first-page":"D901","DOI":"10.1093\/nar\/gkm958","volume":"36","author":"DS Wishart","year":"2008","unstructured":"Wishart, D. S. et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 36, D901\u2013D906 (2008).","journal-title":"Nucleic Acids Res."},{"key":"7_CR19","doi-asserted-by":"publisher","first-page":"D1100","DOI":"10.1093\/nar\/gkr777","volume":"40","author":"A Gaulton","year":"2012","unstructured":"Gaulton, A. et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100\u2013D1107 (2012).","journal-title":"Nucleic Acids Res."},{"key":"7_CR20","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","volume":"55","author":"T Sterling","year":"2015","unstructured":"Sterling, T. & Irwin, J. J. ZINC 15 \u2013 ligand discovery for everyone. J. Chem. Inf. Model. 55, 2324\u20132337 (2015).","journal-title":"J. Chem. Inf. Model."},{"key":"7_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69337-9","volume":"10","author":"R Yoshino","year":"2020","unstructured":"Yoshino, R., Yasuo, N. & Sekijima, M. Identification of key interactions between SARS-CoV-2 main protease and inhibitor drug candidates. Sci. Rep. 10, 12493 (2020).","journal-title":"Sci. Rep."},{"key":"7_CR22","doi-asserted-by":"publisher","unstructured":"Al-Khafaji, K., Al-Duhaidahawi, D. & Taskin Tok, T. Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2. J. Biomol. Struct. Dyn. https:\/\/doi.org\/10.1080\/07391102.2020.1764392 (2020).","DOI":"10.1080\/07391102.2020.1764392"},{"key":"7_CR23","doi-asserted-by":"publisher","unstructured":"Alamri, M. A. et al. Pharmacoinformatics and molecular dynamic simulation studies reveal potential inhibitors of SARS-CoV-2 main protease 3CLpro. J. Biomol. Struct. Dyn. https:\/\/doi.org\/10.1080\/07391102.2020.1782768 (2020).","DOI":"10.1080\/07391102.2020.1782768"},{"key":"7_CR24","doi-asserted-by":"publisher","unstructured":"Arya, R., Das, A., Prashar, V. & Kumar, M. Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs. Preprint at https:\/\/doi.org\/10.26434\/chemrxiv.11860011.v2 (2020).","DOI":"10.26434\/chemrxiv.11860011.v2"},{"key":"7_CR25","doi-asserted-by":"publisher","unstructured":"Chang, Y.-C. et al. Potential therapeutic agents for COVID-19 based on the analysis of protease and RNA polymerase docking. Preprint at https:\/\/doi.org\/10.20944\/preprints202002.0242.v1 (2020).","DOI":"10.20944\/preprints202002.0242.v1"},{"key":"7_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.12688\/f1000research.22457.2","volume":"9","author":"YW Chen","year":"2020","unstructured":"Chen, Y. W., Yiu, C.-P. B. & Wong, K.-Y. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Res. 9, 129 (2020).","journal-title":"F1000Res."},{"key":"7_CR27","doi-asserted-by":"publisher","first-page":"117592","DOI":"10.1016\/j.lfs.2020.117592","volume":"253","author":"AA Elfiky","year":"2020","unstructured":"Elfiky, A. A. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci. 253, 117592 (2020).","journal-title":"Life Sci."},{"key":"7_CR28","doi-asserted-by":"publisher","unstructured":"Elfiky, A. & Ibrahim, N. S. Anti-SARS and anti-HCV drugs repurposing against the Papain-like protease of the newly emerged coronavirus (2019-nCoV). Preprint at https:\/\/doi.org\/10.21203\/rs.2.23280\/v1 (2020).","DOI":"10.21203\/rs.2.23280\/v1"},{"key":"7_CR29","doi-asserted-by":"publisher","unstructured":"Gao, K., Nguyen, D. D., Wang, R. & Wei, G.-W. Machine intelligence design of 2019-nCoV drugs. Preprint at https:\/\/doi.org\/10.1101\/2020.01.30.927889 (2020).","DOI":"10.1101\/2020.01.30.927889"},{"key":"7_CR30","doi-asserted-by":"publisher","unstructured":"Gupta, M. K. et al. In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel. J. Biomol. Struct. Dyn. https:\/\/doi.org\/10.1080\/07391102.2020.1751300 (2020).","DOI":"10.1080\/07391102.2020.1751300"},{"key":"7_CR31","doi-asserted-by":"publisher","first-page":"101646","DOI":"10.1016\/j.tmaid.2020.101646","volume":"35","author":"DC Hall","year":"2020","unstructured":"Hall, D. C. & Ji, H.-F. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med. Infect. Dis. 35, 101646 (2020).","journal-title":"Travel Med. Infect. Dis."},{"key":"7_CR32","doi-asserted-by":"crossref","unstructured":"Hosseini, F. S. & Amanlou, M. Simeprevir, potential candidate to repurpose for coronavirus infection: virtual screening and molecular docking study. Life Sci. 258, 118205 (2020).","DOI":"10.1016\/j.lfs.2020.118205"},{"key":"7_CR33","doi-asserted-by":"publisher","unstructured":"Khan, R. J. et al. Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2\u2032-O-ribose methyltransferase. J. Biomol. Struct. Dyn. https:\/\/doi.org\/10.1080\/07391102.2020.1753577 (2020).","DOI":"10.1080\/07391102.2020.1753577"},{"key":"7_CR34","doi-asserted-by":"publisher","unstructured":"Khan, S. A., Zia, K., Ashraf, S., Uddin, R. & Ul-Haq, Z. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach. J. Biomol. Struct. Dyn. https:\/\/doi.org\/10.1080\/07391102.2020.1751298 (2020).","DOI":"10.1080\/07391102.2020.1751298"},{"key":"7_CR35","doi-asserted-by":"publisher","unstructured":"Li, Y. et al. Therapeutic drugs targeting 2019-nCoV main protease by high-throughput screening. Preprint at https:\/\/doi.org\/10.1101\/2020.01.28.922922 (2020).","DOI":"10.1101\/2020.01.28.922922"},{"key":"7_CR36","doi-asserted-by":"publisher","unstructured":"Lin, S., Shen, R., He, J., Li, X. & Guo, X. Molecular modeling evaluation of the binding effect of ritonavir, lopinavir and darunavir to severe acute respiratory syndrome coronavirus 2 proteases. Preprint at https:\/\/doi.org\/10.1101\/2020.01.31.929695 (2020).","DOI":"10.1101\/2020.01.31.929695"},{"key":"7_CR37","doi-asserted-by":"publisher","unstructured":"Muralidharan, N., Sakthivel, R., Velmurugan, D. & Gromiha, M. M. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19. J. Biomol. Struct. Dyn. https:\/\/doi.org\/10.1080\/07391102.2020.1752802 (2020).","DOI":"10.1080\/07391102.2020.1752802"},{"key":"7_CR38","doi-asserted-by":"publisher","unstructured":"Smith, M. & Smith, J. C. Repurposing therapeutics for COVID-19: supercomputer-based docking to the SARS-CoV-2 viral spike protein and viral spike protein-human ACE2 interface. Preprint at https:\/\/doi.org\/10.26434\/chemrxiv.11871402.v4 (2020).","DOI":"10.26434\/chemrxiv.11871402.v4"},{"key":"7_CR39","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1021\/acs.jcim.0c00179","volume":"60","author":"J Wang","year":"2020","unstructured":"Wang, J. Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing Study. J. Chem. Inf. Model. 60, 3277\u20133286 (2020).","journal-title":"J. Chem. Inf. Model."},{"key":"7_CR40","doi-asserted-by":"crossref","unstructured":"Wu, C. et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm. Sin. B 10, 766\u2013788 (2020).","DOI":"10.1016\/j.apsb.2020.02.008"},{"key":"7_CR41","doi-asserted-by":"publisher","unstructured":"Xu, Z. et al. Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. Preprint at https:\/\/doi.org\/10.1101\/2020.01.27.921627 (2020).","DOI":"10.1101\/2020.01.27.921627"},{"key":"7_CR42","doi-asserted-by":"publisher","first-page":"e2000028","DOI":"10.1002\/minf.202000028","volume":"39","author":"A-T Ton","year":"2020","unstructured":"Ton, A.-T., Gentile, F., Hsing, M., Ban, F. & Cherkasov, A. Rapid identification of potential inhibitors of SARS-CoV-2 main protease by deep docking of 1.3 billion compounds. Mol. Inform. 39, e2000028 (2020).","journal-title":"Mol. Inform."},{"key":"7_CR43","doi-asserted-by":"publisher","unstructured":"Talluri, S. Virtual high throughput screening based prediction of potential drugs for COVID-19. Preprint at https:\/\/doi.org\/10.20944\/preprints202002.0418.v1 (2020).","DOI":"10.20944\/preprints202002.0418.v1"},{"key":"7_CR44","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.csbj.2020.03.025","volume":"18","author":"BR Beck","year":"2020","unstructured":"Beck, B. R., Shin, B., Choi, Y., Park, S. & Kang, K. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput. Struct. Biotechnol. J. 18, 784\u2013790 (2020).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"7_CR45","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/nprot.2016.051","volume":"11","author":"S Forli","year":"2016","unstructured":"Forli, S. et al. Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nat. Protoc. 11, 905\u2013919 (2016).","journal-title":"Nat. Protoc."},{"key":"7_CR46","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1021\/jm030644s","volume":"47","author":"TA Halgren","year":"2004","unstructured":"Halgren, T. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 47, 1750\u20131759 (2004).","journal-title":"J. Med. Chem."},{"key":"7_CR47","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1021\/acscentsci.0c00229","volume":"6","author":"F Gentile","year":"2020","unstructured":"Gentile, F. et al. Deep Docking: a deep learning platform for augmentation of structure based drug discovery. ACS Cent. Sci. 6, 939\u2013949 (2020).","journal-title":"ACS Cent. Sci."},{"key":"7_CR48","doi-asserted-by":"crossref","unstructured":"Torres, P. H. M., Sodero, A. C. R., Jofily, P. & Silva, F. P. Jr Key topics in molecular docking for drug design. Int. J. Mol. Sci. 20, 4574 (2019).","DOI":"10.3390\/ijms20184574"},{"key":"7_CR49","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10822-019-00237-5","volume":"34","author":"DD Nguyen","year":"2020","unstructured":"Nguyen, D. D., Gao, K., Wang, M. & Wei, G.-W. MathDL: mathematical deep learning for D3R Grand Challenge 4. J. Comput. Aided Mol. Des. 34, 131\u2013147 (2020).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"7_CR50","doi-asserted-by":"publisher","unstructured":"Nguyen, D. D., Gao, K., Chen, J., Wang, R. & Wei, G.-W. Potentially highly potent drugs for 2019-nCoV. Preprint at https:\/\/doi.org\/10.1101\/2020.02.05.936013 (2020).","DOI":"10.1101\/2020.02.05.936013"},{"key":"7_CR51","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1021\/ci00057a005","volume":"28","author":"D Weininger","year":"1988","unstructured":"Weininger, D. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules. J. Chem. Inf. Comput. Sci. 28, 31\u201336 (1988).","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"7_CR52","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.antiviral.2012.09.013","volume":"96","author":"SM-Y Lee","year":"2012","unstructured":"Lee, S. M.-Y. & Yen, H.-L. Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection. Antiviral Res. 96, 391\u2013404 (2012).","journal-title":"Antiviral Res."},{"key":"7_CR53","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nbt0310-239","volume":"28","author":"J-Y Min","year":"2010","unstructured":"Min, J.-Y. & Subbarao, K. Cellular targets for influenza drugs. Nat. Biotechnol. 28, 239\u2013240 (2010).","journal-title":"Nat. Biotechnol."},{"key":"7_CR54","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41392-020-0191-1","volume":"5","author":"M Catanzaro","year":"2020","unstructured":"Catanzaro, M. et al. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct. Target. Ther. 5, 84 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"7_CR55","doi-asserted-by":"publisher","first-page":"100037","DOI":"10.1016\/j.medidd.2020.100037","volume":"5","author":"J Liao","year":"2020","unstructured":"Liao, J., Way, G. & Madahar, V. Target virus or target ourselves for COVID-19 drugs discovery?\u2015Lessons learned from anti-influenza virus therapies. Medi. Drug Discov. 5, 100037 (2020).","journal-title":"Medi. Drug Discov."},{"key":"7_CR56","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1056\/NEJMc2009226","volume":"382","author":"L Chen","year":"2020","unstructured":"Chen, L. et al. Clinical characteristics of pregnant women with Covid-19 in Wuhan, China. N. Engl. J. Med. 382, e100 (2020).","journal-title":"N. Engl. J. Med."},{"key":"7_CR57","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929\u20131935 (2006).","journal-title":"Science"},{"key":"7_CR58","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian, A. et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell 171, 1437\u20131452.e17 (2017).","journal-title":"Cell"},{"key":"7_CR59","doi-asserted-by":"publisher","first-page":"e9357","DOI":"10.7717\/peerj.9357","volume":"8","author":"T Loganathan","year":"2020","unstructured":"Loganathan, T., Ramachandran, S., Shankaran, P., Nagarajan, D. & Mohan, S. S. Host transcriptome-guided drug repurposing for COVID-19 treatment: a meta-analysis based approach. PeerJ 8, e9357 (2020).","journal-title":"PeerJ"},{"key":"7_CR60","doi-asserted-by":"crossref","unstructured":"Jia, Z., Song, X., Shi, J., Wang, W. & He, K. Transcriptome-based drug repositioning for coronavirus disease 2019 (COVID-19). Pathog. Dis. 78, ftaa036 (2020).","DOI":"10.1093\/femspd\/ftaa036"},{"key":"7_CR61","unstructured":"Law, J. N. et al. Identifying human interactors of SARS-CoV-2 proteins and drug targets for COVID-19 using network-based label propagation. Preprint at https:\/\/arxiv.org\/abs\/2006.01968 (2020)."},{"key":"7_CR62","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280.e8 (2020).","journal-title":"Cell"},{"key":"7_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02405-w","volume":"18","author":"F Messina","year":"2020","unstructured":"Messina, F. et al. COVID-19: viral\u2013host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection. J. Transl. Med. 18, 233 (2020).","journal-title":"J. Transl. Med."},{"key":"7_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17189-2","volume":"11","author":"S Sadegh","year":"2020","unstructured":"Sadegh, S. et al. Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing. Nat. Commun. 11, 3518 (2020).","journal-title":"Nat. Commun."},{"key":"7_CR65","doi-asserted-by":"crossref","unstructured":"Gy\u00f6ngyi, Z., Garcia-Molina, H. & Pedersen, J. Combating web spam with TrustRank. In Proc. 2004 VLDB Conference (eds. Nascimento, M. A. et al.) 576\u2013587 (Morgan Kaufmann, 2004).","DOI":"10.1016\/B978-012088469-8.50052-8"},{"key":"7_CR66","unstructured":"Brin, S. & Page, L. The anatomy of a large-scale hypertextual web search engine. 30, 107\u2013117 (1998)."},{"key":"7_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05116-5","volume":"9","author":"F Cheng","year":"2018","unstructured":"Cheng, F. et al. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat. Commun. 9, 2691 (2018).","journal-title":"Nat. Commun."},{"key":"7_CR68","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","volume":"6","author":"Y Zhou","year":"2020","unstructured":"Zhou, Y. et al. Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2. Cell Discov 6, 14 (2020).","journal-title":"Cell Discov"},{"key":"7_CR69","unstructured":"Gysi, D. M. et al. Network medicine framework for identifying drug repurposing opportunities for COVID-19. Preprint at https:\/\/arxiv.org\/abs\/2004.07229 (2020)."},{"key":"7_CR70","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkw373","volume":"44","author":"M List","year":"2016","unstructured":"List, M. et al. KeyPathwayMinerWeb: online multi-omics network enrichment. Nucleic Acids Res. 44, W98\u2013W104 (2016).","journal-title":"Nucleic Acids Res."},{"key":"7_CR71","doi-asserted-by":"crossref","unstructured":"Belyaeva, A. et al. Causal network models of SARS-CoV-2 expression and aging to identify candidates for drug repurposing. Preprint at https:\/\/arxiv.org\/abs\/2006.03735 (2020).","DOI":"10.1038\/s41467-021-21056-z"},{"key":"7_CR72","doi-asserted-by":"publisher","unstructured":"Ge, Y. et al. A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. Preprint at https:\/\/doi.org\/10.1101\/2020.03.11.986836 (2020).","DOI":"10.1101\/2020.03.11.986836"},{"key":"7_CR73","unstructured":"Favipiravir plus hydroxychloroquine and lopinavir\/ritonavir plus hydroxychloroquine in COVID-19. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04376814 (2020)."},{"key":"7_CR74","unstructured":"Baricitinib therapy in COVID-19. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04358614 (2020)."},{"key":"7_CR75","unstructured":"Lopinavir\/ritonavir, ribavirin and IFN-beta combination for nCoV treatment. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04276688 (2020)."},{"key":"7_CR76","unstructured":"An investigation into beneficial effects of interferon beta 1a, compared to interferon beta 1b and the base therapeutic regiment in moderate to severe COVID-19: a randomized clinical trial. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04343768 (2020)."},{"key":"7_CR77","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao, B. et al. A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med. 382, 1787\u20131799 (2020).","journal-title":"N. Engl. J. Med."},{"key":"7_CR78","unstructured":"Lopinavir-Ritonavir results. RECOVERY trial (2020); https:\/\/www.recoverytrial.net\/results\/lopinavar-results"},{"key":"7_CR79","unstructured":"\u2018Solidarity\u2019 clinical trial for COVID-19 treatments. WHO (accessed November 2020); https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/global-research-on-novel-coronavirus-2019-ncov\/solidarity-clinical-trial-for-covid-19-treatments"},{"key":"7_CR80","unstructured":"Trial of treatments for COVID-19 in hospitalized adults. ClinicalTrials.gov (2020); https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04315948"},{"key":"7_CR81","doi-asserted-by":"crossref","unstructured":"Beigel, J. H. et al. Remdesivir for the treatment of Covid-19. N. Engl. J. Med. 383, 1813\u20131826 (2020).","DOI":"10.1056\/NEJMc2022236"},{"key":"7_CR82","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","volume":"382","author":"J Grein","year":"2020","unstructured":"Grein, J. et al. Compassionate use of remdesivir for patients with severe Covid-19. N. Engl. J. Med. 382, 2327\u20132336 (2020).","journal-title":"N. Engl. J. Med."},{"key":"7_CR83","unstructured":"Goldman, J. D. et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N. Engl. J. Med. 383, 1827\u20131837 (2020)."},{"key":"7_CR84","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269\u2013271 (2020).","journal-title":"Cell Res."},{"key":"7_CR85","doi-asserted-by":"publisher","first-page":"6789","DOI":"10.1021\/jm0608356","volume":"49","author":"N Huang","year":"2006","unstructured":"Huang, N., Shoichet, B. K. & Irwin, J. J. Benchmarking sets for molecular docking. J. Med. Chem. 49, 6789\u20136801 (2006).","journal-title":"J. Med. Chem."},{"key":"7_CR86","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1021\/jm030580l","volume":"47","author":"R Wang","year":"2004","unstructured":"Wang, R., Fang, X., Lu, Y. & Wang, S. The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures. J. Med. Chem. 47, 2977\u20132980 (2004).","journal-title":"J. Med. Chem."},{"key":"7_CR87","doi-asserted-by":"publisher","unstructured":"The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. New Engl. J. Med. https:\/\/doi.org\/10.1056\/nejmoa2021436 (2020).","DOI":"10.1056\/nejmoa2021436"},{"key":"7_CR88","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1001\/jama.2020.17023","volume":"324","author":"WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group.","year":"2020","unstructured":"WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 324, 1330\u20131341 (2020).","journal-title":"JAMA"},{"key":"7_CR89","doi-asserted-by":"publisher","first-page":"104854","DOI":"10.1016\/j.phrs.2020.104854","volume":"157","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y., Xu, Q., Sun, Z. & Zhou, L. Current targeted therapeutics against COVID-19: Based on first-line experience in China. Pharmacol. Res. 157, 104854 (2020).","journal-title":"Pharmacol. Res."},{"key":"7_CR90","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Z Jin","year":"2020","unstructured":"Jin, Z. et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 582, 289\u2013293 (2020).","journal-title":"Nature"},{"key":"7_CR91","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.drudis.2016.05.015","volume":"21","author":"W Sun","year":"2016","unstructured":"Sun, W., Sanderson, P. E. & Zheng, W. Drug combination therapy increases successful drug repositioning. Drug Discov. Today 21, 1189\u20131195 (2016).","journal-title":"Drug Discov. Today"},{"key":"7_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-019-3288-1","volume":"20","author":"H Liu","year":"2019","unstructured":"Liu, H. et al. Predicting effective drug combinations using gradient tree boosting based on features extracted from drug-protein heterogeneous network. BMC Bioinform. 20, 645 (2019).","journal-title":"BMC Bioinform."},{"key":"7_CR93","doi-asserted-by":"publisher","unstructured":"Brimacombe, K. R. et al. An OpenData portal to share COVID-19 drug repurposing data in real time. Preprint at https:\/\/doi.org\/10.1101\/2020.06.04.135046 (2020).","DOI":"10.1101\/2020.06.04.135046"},{"key":"7_CR94","doi-asserted-by":"publisher","first-page":"10750","DOI":"10.1073\/pnas.1810137115","volume":"115","author":"J Janes","year":"2018","unstructured":"Janes, J. et al. The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis. Proc. Natl Acad. Sci. USA 115, 10750\u201310755 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"7_CR95","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.5958\/0974-360X.2016.00353.X","volume":"9","author":"S Syed Shihaab","year":"2016","unstructured":"Syed Shihaab, S. & Pradeep Chlorhexidine: its properties and effects. Res. J. Pharm. Technol. 9, 1755\u20131760 (2016).","journal-title":"Res. J. Pharm. Technol."},{"key":"7_CR96","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13321-020-00450-7","volume":"12","author":"TN Jarada","year":"2020","unstructured":"Jarada, T. N., Rokne, J. G. & Alhajj, R. A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions. J. Cheminform. 12, 46 (2020).","journal-title":"J. Cheminform."}],"container-title":["Nature Computational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43588-020-00007-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43588-020-00007-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43588-020-00007-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T22:14:43Z","timestamp":1674857683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43588-020-00007-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,14]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["7"],"URL":"https:\/\/doi.org\/10.1038\/s43588-020-00007-6","relation":{},"ISSN":["2662-8457"],"issn-type":[{"value":"2662-8457","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,14]]},"assertion":[{"value":"16 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}